Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-loaded, Dendritic Cell (TLPLDC) Vaccine to Prevent Recurrence of Resected Stage 3/4 Melanoma Patients: Results of a Phase 1/2A Trial
Abstract
In a randomized, double-blind phase 2 trial, there were no differences in DFS or OS in clinically disease-free melanoma pts receiving TLPLDC versus TLPO vaccines. Given prior efficacy shown with TLPLDC, further testing for efficacy of these two vaccines is warranted in a phase 3 trial.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2021
- Accession Number
- AD1151896
Entities
People
- Adam C. Berger
- Alexandra M. Adams
- Ankur Tiwari
- Anne E. O'shea
- Annelies T. Hickerson
- Diane F. Hale
- Elizabeth L. Carpenter
- Franklin A. Valdera
- George E. Peoples
- Guy T. Clifton
- James W. Jakub
- Jeffrey J. Sussman
- Jessica L. Cindass
- John Hyngstrom
- John W. Iii Myers
- Mark B Faries
- Montaser Shaheen
- Patrick M. Mccarthy
- Phillip M Kemp Bohan
- Robert C. Chick
- Thomas Wagner
- Timothy J Vreeland
- Xianzhong Yu
Organizations
- 59th Medical Wing
- Angeles Clinic Foundation
- Clemson University
- Mayo Clinic
- Orbis Health Solutions (United States)
- San Antonio Military Medical Center
- University of Arizona
- University of Cincinnati
- University of Texas Health Science Center at San Antonio
- University of Utah